CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Serological screening for IgG and IgM antibodies against COVID-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug658 Convalescent plasma Wiki 0.25

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 COVID-19 Serologic Screening and a Strict Protocol in the Management of a Referral Gastrointestinal Endoscopy Unit: a Prospective Study

The novel COronaVIrus Disease 19 (COVID-19) outbreak has impacted daily activities in nearly 210 countries and territories worldwide. In Ecuador, the city of Guayaquil has nearly two-thirds of the COVID-positive patients in the country and nearly 40% of infected individuals are health-care related personnel. Nonemergent, emergent and urgent endoscopic procedures are necessary to be performed during the COVID-19 pandemic. Several experiences in the management of the endoscopic unit during the pandemic has been proposed. We aimed to prospectively evaluate a strict protocol for preventing potential nosocomial infection of COVID-19.

NCT04374123 COVID Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19

Primary Outcomes

Description: COVID-19 infection in the staff documented via PCR

Measure: Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.

Time: through study completion, an average of 30 days

Description: Endoscopic records of patients treated during the COVID-19 protocol

Measure: Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.

Time: through study completion, an average 30 days

Description: technical success of endoscopic procedures

Measure: Technical success rate of endoscopic procedures during the 30-days study period.

Time: through study completion, an average 30 days

Description: serum levels of IgG and IgM against COVID-19

Measure: IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.

Time: through study completion, an average 30 days

Description: adverse events of endoscopic procedures

Measure: Adverse events rate of endoscopic procedures during the 30-days

Time: through study completion, an average 30 days


No related HPO nodes (Using clinical trials)